The University of Chicago Header Logo

Connection

Kenneth Gordon to Psoriasis

Back to Details
This is a "connection" page, showing publications Kenneth Gordon has written about Psoriasis.
Kenneth Gordon
Connection Strength
33.489
Psoriasis
  1. Bimekizumab for the treatment of psoriasis. Immunotherapy. 2024 Apr; 16(7):431-446.
    View in: PubMed
    Score: 0.775
  2. Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply. Lancet Rheumatol. 2023 Jun; 5(6):e313.
    View in: PubMed
    Score: 0.733
  3. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023 Apr; 5(4):e200-e207.
    View in: PubMed
    Score: 0.721
  4. Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022 Nov; 14(16):1279-1290.
    View in: PubMed
    Score: 0.706
  5. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 07 01; 158(7):735-744.
    View in: PubMed
    Score: 0.688
  6. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022 03; 186(3):466-475.
    View in: PubMed
    Score: 0.660
  7. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 02 06; 397(10273):475-486.
    View in: PubMed
    Score: 0.625
  8. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020 Dec; 21(6):881-890.
    View in: PubMed
    Score: 0.617
  9. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020 12 01; 156(12):1344-1353.
    View in: PubMed
    Score: 0.617
  10. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 04; 184(4):652-662.
    View in: PubMed
    Score: 0.607
  11. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2022 Feb; 33(1):219-228.
    View in: PubMed
    Score: 0.592
  12. Comparative Effectiveness Studies for Psoriasis-The Methods Matter. JAMA Dermatol. 2020 03 01; 156(3):253-255.
    View in: PubMed
    Score: 0.586
  13. Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370.
    View in: PubMed
    Score: 0.569
  14. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2020 Dec; 31(8):763-768.
    View in: PubMed
    Score: 0.561
  15. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 12; 139(12):2437-2446.e1.
    View in: PubMed
    Score: 0.557
  16. Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance. JAMA Dermatol. 2018 10 01; 154(10):1135.
    View in: PubMed
    Score: 0.531
  17. IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg. 2018 Sep; 37(3):158-162.
    View in: PubMed
    Score: 0.528
  18. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
    View in: PubMed
    Score: 0.525
  19. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.
    View in: PubMed
    Score: 0.523
  20. Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg. 2018 Feb; 37(2S):S44-S47.
    View in: PubMed
    Score: 0.507
  21. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 01; 178(1):132-139.
    View in: PubMed
    Score: 0.502
  22. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017 Dec; 77(6):1030-1037.
    View in: PubMed
    Score: 0.496
  23. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
    View in: PubMed
    Score: 0.470
  24. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 11 24; 375(21):2102.
    View in: PubMed
    Score: 0.467
  25. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 02; 28(1):3-7.
    View in: PubMed
    Score: 0.458
  26. Translating the Science of Psoriasis. Semin Cutan Med Surg. 2016 Jun; 35(4 Suppl 4):S64.
    View in: PubMed
    Score: 0.452
  27. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76.
    View in: PubMed
    Score: 0.402
  28. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec; 71(6):1176-82.
    View in: PubMed
    Score: 0.401
  29. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-15.
    View in: PubMed
    Score: 0.386
  30. Understanding therapeutic pathways and comorbidities in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S20-3.
    View in: PubMed
    Score: 0.386
  31. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S37-41.
    View in: PubMed
    Score: 0.386
  32. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013 Dec; 169(6):1337-41.
    View in: PubMed
    Score: 0.380
  33. Systemics to topicals in psoriasis: the unfilled need. Br J Dermatol. 2013 Jul; 169(1):2-3.
    View in: PubMed
    Score: 0.369
  34. Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013 Jul; 9(7):677-82.
    View in: PubMed
    Score: 0.369
  35. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb; 132(2):304-14.
    View in: PubMed
    Score: 0.328
  36. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51.
    View in: PubMed
    Score: 0.327
  37. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2):241-51.
    View in: PubMed
    Score: 0.322
  38. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010 Mar; 29(1):48-52.
    View in: PubMed
    Score: 0.293
  39. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010 Feb; 146(2):186-8.
    View in: PubMed
    Score: 0.291
  40. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009 Sep-Oct; 22(5):431-40.
    View in: PubMed
    Score: 0.283
  41. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol. 2007 Dec; 6(12):1205-12.
    View in: PubMed
    Score: 0.251
  42. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct; 55(4):598-606.
    View in: PubMed
    Score: 0.229
  43. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S101-11.
    View in: PubMed
    Score: 0.222
  44. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S85-91.
    View in: PubMed
    Score: 0.222
  45. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006; 17(1):9-17.
    View in: PubMed
    Score: 0.219
  46. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov; 153(5):945-53.
    View in: PubMed
    Score: 0.217
  47. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005 Sep; 27(9):1317-28.
    View in: PubMed
    Score: 0.214
  48. Patient education and advocacy groups: a means to better outcomes? Arch Dermatol. 2005 Jan; 141(1):80-1.
    View in: PubMed
    Score: 0.205
  49. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan; 141(1):82-4.
    View in: PubMed
    Score: 0.205
  50. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg. 2004 Dec; 8 Suppl 2:3-9.
    View in: PubMed
    Score: 0.203
  51. From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004 Oct; 22(4):371-7, vii-viii.
    View in: PubMed
    Score: 0.201
  52. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 Mar 15; 190(4):477-485.
    View in: PubMed
    Score: 0.194
  53. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024 Feb 01; 160(2):204-209.
    View in: PubMed
    Score: 0.192
  54. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004; 17(5):427-31.
    View in: PubMed
    Score: 0.191
  55. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80.
    View in: PubMed
    Score: 0.190
  56. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003 Dec; 139(12):1563-70.
    View in: PubMed
    Score: 0.190
  57. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003 Dec; 2(6):624-8.
    View in: PubMed
    Score: 0.190
  58. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003 Nov; 49(5):816-25.
    View in: PubMed
    Score: 0.189
  59. The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases. Adv Ther. 2023 11; 40(11):5090-5101.
    View in: PubMed
    Score: 0.187
  60. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 10 28; 402(10412):1541-1551.
    View in: PubMed
    Score: 0.187
  61. Evolution of biologic therapies for the treatment of psoriasis. Skinmed. 2003 Sep-Oct; 2(5):286-94.
    View in: PubMed
    Score: 0.187
  62. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S44-50.
    View in: PubMed
    Score: 0.186
  63. Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines. Pediatr Dermatol. 2023 Sep-Oct; 40(5):789-808.
    View in: PubMed
    Score: 0.184
  64. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023 08; 15(11):787-797.
    View in: PubMed
    Score: 0.182
  65. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51.
    View in: PubMed
    Score: 0.175
  66. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002 May; 138(5):657-63.
    View in: PubMed
    Score: 0.170
  67. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002; 25(13):913-27.
    View in: PubMed
    Score: 0.166
  68. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
    View in: PubMed
    Score: 0.165
  69. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 12; 185(6):1146-1159.
    View in: PubMed
    Score: 0.163
  70. Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022 Jun; 33(4):2085-2093.
    View in: PubMed
    Score: 0.159
  71. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 02 06; 397(10273):487-498.
    View in: PubMed
    Score: 0.156
  72. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb; 84(2):432-470.
    View in: PubMed
    Score: 0.151
  73. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020 Dec; 34(12):2830-2838.
    View in: PubMed
    Score: 0.150
  74. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1445-1486.
    View in: PubMed
    Score: 0.146
  75. Defining drug-free remission of skin disease in patients with plaque psoriasis. Br J Dermatol. 2020 06; 182(6):1484-1487.
    View in: PubMed
    Score: 0.145
  76. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology. 2021; 237(1):46-55.
    View in: PubMed
    Score: 0.145
  77. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020 06; 182(6):1348-1358.
    View in: PubMed
    Score: 0.145
  78. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
    View in: PubMed
    Score: 0.144
  79. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.
    View in: PubMed
    Score: 0.143
  80. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan; 82(1):161-201.
    View in: PubMed
    Score: 0.143
  81. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
    View in: PubMed
    Score: 0.143
  82. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Dec; 46(12):1141-1152.
    View in: PubMed
    Score: 0.143
  83. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep; 81(3):775-804.
    View in: PubMed
    Score: 0.140
  84. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr; 80(4):1073-1113.
    View in: PubMed
    Score: 0.136
  85. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072.
    View in: PubMed
    Score: 0.136
  86. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 10 04; 379(14):1313-1321.
    View in: PubMed
    Score: 0.132
  87. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Br J Dermatol. 2018 10; 179(4):984-986.
    View in: PubMed
    Score: 0.131
  88. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Aug; 32(8):1297-1304.
    View in: PubMed
    Score: 0.131
  89. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 06 01; 154(6):676-683.
    View in: PubMed
    Score: 0.130
  90. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328.
    View in: PubMed
    Score: 0.129
  91. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6.
    View in: PubMed
    Score: 0.128
  92. The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018 Feb; 37(2S):S39-S43.
    View in: PubMed
    Score: 0.127
  93. Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S48-S51.
    View in: PubMed
    Score: 0.127
  94. Practical Strategies for Optimizing Management of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S52-S55.
    View in: PubMed
    Score: 0.127
  95. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179.
    View in: PubMed
    Score: 0.121
  96. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1004-1013.
    View in: PubMed
    Score: 0.120
  97. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun; 76(6):1045-1053.e3.
    View in: PubMed
    Score: 0.119
  98. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016 Aug; 75(2):287-96.
    View in: PubMed
    Score: 0.113
  99. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28; 375(4):345-56.
    View in: PubMed
    Score: 0.113
  100. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01; 152(6):661-9.
    View in: PubMed
    Score: 0.113
  101. The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016 Jul; 75(1):33-41.
    View in: PubMed
    Score: 0.113
  102. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul; 75(1):77-82.e7.
    View in: PubMed
    Score: 0.113
  103. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct; 373(14):1318-28.
    View in: PubMed
    Score: 0.108
  104. The experience of pain and redness in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2015 Oct; 26(5):401-5.
    View in: PubMed
    Score: 0.107
  105. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44.
    View in: PubMed
    Score: 0.106
  106. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul; 73(1):37-49.
    View in: PubMed
    Score: 0.106
  107. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016 May; 30(5):864-5.
    View in: PubMed
    Score: 0.104
  108. Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. JAMA. 2014 Dec 24-31; 312(24):2676-7.
    View in: PubMed
    Score: 0.102
  109. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014 Sep-Oct; 24(5):523-32.
    View in: PubMed
    Score: 0.100
  110. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013 Aug; 24(4):255-60.
    View in: PubMed
    Score: 0.092
  111. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27(12):1535-45.
    View in: PubMed
    Score: 0.089
  112. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct; 24(5):356-60.
    View in: PubMed
    Score: 0.089
  113. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
    View in: PubMed
    Score: 0.088
  114. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72.
    View in: PubMed
    Score: 0.085
  115. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12.
    View in: PubMed
    Score: 0.084
  116. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012 Aug; 67(2):245-56.
    View in: PubMed
    Score: 0.082
  117. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.
    View in: PubMed
    Score: 0.081
  118. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74.
    View in: PubMed
    Score: 0.078
  119. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb; 64(2):263-74.
    View in: PubMed
    Score: 0.077
  120. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56.
    View in: PubMed
    Score: 0.075
  121. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.074
  122. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan; 62(1):114-135.
    View in: PubMed
    Score: 0.071
  123. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul; 61(1 Suppl 1):S1-S46.
    View in: PubMed
    Score: 0.070
  124. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr; 60(4):643-59.
    View in: PubMed
    Score: 0.068
  125. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008 Dec 15; 102(12):1631-43.
    View in: PubMed
    Score: 0.067
  126. Rethinking eligibility creep. J Am Acad Dermatol. 2008 Jul; 59(1):165-7; author reply 167.
    View in: PubMed
    Score: 0.065
  127. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371(9625):1665-74.
    View in: PubMed
    Score: 0.065
  128. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
    View in: PubMed
    Score: 0.064
  129. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008 Apr 15; 101(8):1119-26.
    View in: PubMed
    Score: 0.064
  130. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008 Jun; 58(6):1031-42.
    View in: PubMed
    Score: 0.064
  131. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008 Feb; 144(2):200-7.
    View in: PubMed
    Score: 0.063
  132. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008 Jan; 58(1):94-105.
    View in: PubMed
    Score: 0.062
  133. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15.
    View in: PubMed
    Score: 0.062
  134. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov; 48(2):87-101.
    View in: PubMed
    Score: 0.061
  135. The first World Psoriasis and Psoriatic Arthritis Conference. J Invest Dermatol. 2007 Jul; 127(7):1566-7.
    View in: PubMed
    Score: 0.061
  136. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007 Jun; 143(6):719-26.
    View in: PubMed
    Score: 0.060
  137. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50.
    View in: PubMed
    Score: 0.059
  138. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr; 56(4):598-603.
    View in: PubMed
    Score: 0.058
  139. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc. 2006 Sep; 11(1):16-29.
    View in: PubMed
    Score: 0.057
  140. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-14.
    View in: PubMed
    Score: 0.056
  141. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006 Apr; 54(4 Suppl 1):S164-70.
    View in: PubMed
    Score: 0.056
  142. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 Jan 07; 367(9504):29-35.
    View in: PubMed
    Score: 0.055
  143. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005 Dec; 9(6):303-12.
    View in: PubMed
    Score: 0.055
  144. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May; 152(5):954-60.
    View in: PubMed
    Score: 0.052
  145. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
    View in: PubMed
    Score: 0.052
  146. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8.
    View in: PubMed
    Score: 0.051
  147. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):614-24.
    View in: PubMed
    Score: 0.051
  148. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec; 139(12):1627-32; discussion 1632.
    View in: PubMed
    Score: 0.047
  149. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr; 72(4):517-24.
    View in: PubMed
    Score: 0.021
  150. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011 Mar; 10(3):289-300.
    View in: PubMed
    Score: 0.020
  151. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep; 61(3):451-85.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.